Lumida
/TNGX
⌘K
Tango Therapeutics Inc

Tango Therapeutics Inc

TNGX
$23.78USD+1.75%+0.41 today

MARKET CAP

4.0B

P/E (TTM)

FWD P/E

DAY RANGE

$23 – $25

52W RANGE

$6
$34

AI Summary

Stalk
TrimMedium

TNGX is exhibiting Stage 3 distribution characteristics, with price below declining 9 and 20 EMAs and a recent bounce into the 20 EMA that has not been decisively rejected. The medium-term bias remains bearish, favoring sell-side engagement on rallies. Short-term conditions are neutral, suggesting deferred execution until resistance at the 20/9 EMA zone is confirmed. The long-term uptrend above the 200 DMA is intact but would be threatened by a breakdown below the 50 SMA.

  • 92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer Phase 1/2 trial
  • $1 billion cash as of June 2026 extends funding into late-stage studies
  • Q2 net loss of $55.3 million (-$0.37/share) with $0 collaboration revenue
Full analysis →
Insider Trades21 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Aug 3, 2026SellTNGXAdam CrystalPresident, R&D54,000$16.22$4.0B-30.85%+276.27%$875.9K+0.00%10b5-1Stalk
Jul 1, 2026SellTNGXAdam CrystalPresident, R&D54,000$17.39$4.0B-30.85%+276.27%$939.3K+0.00%10b5-1Stalk
Jun 1, 2026SellTNGXAdam CrystalPresident, R&D54,000$14.04$4.0B-30.85%+276.27%$758.0K+0.00%10b5-1Stalk
May 1, 2026SellTNGXAdam CrystalPresident, R&D54,000$13.21$4.0B-30.85%+276.27%$713.5K+0.00%10b5-1Stalk
Apr 15, 2026SellTNGXAdam CrystalPresident, R&D76,920$15.10$4.0B-30.85%+276.27%$1.2M+0.00%10b5-1Stalk
Apr 1, 2026SellTNGXAdam CrystalPresident, R&D54,000$13.20$4.0B-30.85%+276.27%$712.9K+0.00%10b5-1Stalk
Mar 25, 2026SellTNGXAdam CrystalPresident, R&D24,000$12.65$4.0B-30.85%+276.27%$303.7K+0.00%10b5-1Stalk
Mar 5, 2026SellTNGXAdam CrystalPresident, R&D20,251$15.00$4.0B-30.85%+276.27%$303.8K-15.24%10b5-1Stalk
Feb 25, 2026SellTNGXAdam CrystalPresident, R&D54,345$12.77$4.0B-30.85%+276.27%$694.2K-29.03%10b5-1Stalk
Feb 3, 2026SellTNGXDaniella BeckmanChief Financial Officer10,317$12.26$4.0B-30.85%+276.27%$126.5K-1.60%Stalk
Feb 3, 2026SellTNGXAdam CrystalPresident, R&D18,452$12.26$4.0B-30.85%+276.27%$226.3K-2.72%Stalk
Feb 3, 2026SellTNGXBarbara WeberDirector, Executive Chair30,519$12.26$4.0B-30.85%+276.27%$374.3K-0.87%Stalk
Feb 4, 2025SellTNGXDouglas BarryGeneral Counsel5,330$3.07$4.0B-30.85%+276.27%$16.4K-3.81%Stalk
Feb 4, 2025SellTNGXDaniella BeckmanChief Financial Officer8,232$3.07$4.0B-30.85%+276.27%$25.3K-2.63%Stalk
Feb 4, 2025SellTNGXAdam Crystal14,283$3.07$4.0B-30.85%+276.27%$43.9K-4.23%Stalk
Feb 4, 2025SellTNGXBarbara WeberChief Executive Officer18,791$3.07$4.0B-30.85%+276.27%$57.7K-0.57%Stalk
Feb 6, 2024SellTNGXDouglas BarryGeneral Counsel2,776$12.59$4.0B-30.85%+276.27%$35.0K-3.01%Stalk
Feb 6, 2024SellTNGXDaniella BeckmanChief Financial Officer3,725$12.59$4.0B-30.85%+276.27%$46.9K-1.38%Stalk
Feb 6, 2024SellTNGXAdam Crystal8,371$12.59$4.0B-30.85%+276.27%$105.4K-3.33%Stalk
Feb 6, 2024SellTNGXBarbara WeberChief Executive Officer9,138$12.59$4.0B-30.85%+276.27%$115.1K-0.30%Stalk
Nov 1, 2023SellTNGXAdam Crystal7,507$8.39$4.0B-30.85%+276.27%$63.0K-8.46%Stalk